EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
Executive Summary
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO says.
You may also be interested in...
EQRx Raises White Flag On Its Low-Cost Drug Business Model
The company is backing out of the development of several clinical-stage assets and will cut 170 positions while it changes its business strategy.
BeiGene Head of R&D Lai Wang On Going Global
The Chinese company's R&D leader discusses the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.
BeiGene Head of R&D Lai Wang On Going Global
The Chinese company's R&D leader talked to Scrip about the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.